Momespray

Composition:

Momespray™: Each spray contains Mometasone Furoate BP 50 meg.

Indication:

Momespray™ is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. It

is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. It is also indicated for the treatment of

nasal polyps in patients 18 years and older.

Dose & Administration:

Administer Mometasone Nasal Spray by the intranasal route only.

Allergic Rhinitis

Adults and Children 12 Years of Age and Older: For prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal

symptoms of perennial allergic rhinitis use two sprays (50 meg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 meg). In patients

with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis use Momespray™ 50 meg (200 meg/day) 2 to 4 weeks prior

to the anticipated start of the pollen season.

Children (2 to 11 years of age) For treatment of the nasal symptoms of seasonal and perennial allergic rhinitis use one spray (50 meg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 meg).

Nasal Polyps

Adults 18 years of Age and Older: For nasal polyps use two sprays (50 meg of Mometasone Furoate in each spray) in each nostril twice daily (total daily dose of 400

meg). A dose of two sprays (50 meg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 meg) is also effective in some patients.

Meltix